Update on Duchenne muscular dystrophy

被引:1
|
作者
Leiva-Cepas, F. [1 ,2 ,3 ,4 ]
Montano Martinez, A. [5 ]
Lopez-Lopez, I [6 ]
机构
[1] Univ Cordoba, Fac Med & Enfermeria, Dept Ciencias Morfol, Secc Histol, Cordoba, Spain
[2] Hosp Univ Reina Sofia, Unidad Gest Clin Anat Patol, Cordoba, Spain
[3] Grp Invest Regenerat Muscular REGMUS, Codigo PAIDI CTS 285, Cordoba, Spain
[4] Inst Maimonides Invest Biomed Cordoba, Grp GC Invest Epidemiol Atenc Primaria 12, Cordoba, Spain
[5] Hosp Montilla, Empresa Publ Hosp Alto Guadalquivir, Cordoba, Spain
[6] Univ Reina Sofia, Serv Nefrol Hosp, Cordoba, Spain
来源
MEDICINA DE FAMILIA-SEMERGEN | 2021年 / 47卷 / 07期
关键词
Duchenne muscular dystrophy; X-linked disease; Recommendations; Steroids; PRIMARY-CARE; MANAGEMENT; DIAGNOSIS; PATIENT;
D O I
10.1016/j.semerg.2021.06.008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Duchenne muscular dystrophy, DMD* (ICD-9-C: 359.1; ICD-10-ES: G71.01, ORPHA: 98896) is a dystrophic type, autosomal recessive myopathy linked to the X chromosome, low incidence 1/3300, with full penetrance and multi-organ involvement (neuro-muscular, respiratory, digestive and metabolic). It has great clinical variability. Symptoms begin in pediatric age (mobility limitation and early respiratory complications). Respiratory complications reduce the life expectancy of those affected. There is no treatment that modifies its evolution, although corticosteroids and new gene therapies are increasing the half-life of this disease. The role of the Primary Care Physician (PCP) is decisive in the monitoring and control of the complications of DMD, either coordinating the different specialties involved in it. (C) 2021 Sociedad Espanola de Medicos de Atencion Primaria (SEMERGEN). Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:472 / 481
页数:10
相关论文
共 50 条
  • [41] Nanotherapy for Duchenne muscular dystrophy
    Nance, Michael E.
    Hakim, Chady H.
    Yang, N. Nora
    Duan, Dongsheng
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2018, 10 (02)
  • [42] Duchenne muscular dystrophy pathophysiology
    Pereon, Y.
    Mercier, S.
    Magot, A.
    ARCHIVES DE PEDIATRIE, 2015, 22 : S18 - S23
  • [43] DUCHENNE MUSCULAR-DYSTROPHY
    HOFFMAN, EP
    RECHERCHE, 1993, 24 (250): : 36 - 44
  • [44] DUCHENNE MUSCULAR-DYSTROPHY
    BERROL, S
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 235 (12): : 1212 - 1212
  • [45] REGENERATION IN DUCHENNE MUSCULAR DYSTROPHY
    MASTAGLI.FL
    PAPADIMI.JM
    KAKULAS, BA
    AUSTRALASIAN ANNALS OF MEDICINE, 1968, 17 (02): : 172 - &
  • [46] Duchenne or Meryon muscular dystrophy?
    Drouin, Emmanuel
    Pereon, Yann
    MOLECULAR GENETICS AND METABOLISM, 2014, 113 (04) : 241 - 242
  • [47] Adults with Duchenne Muscular Dystrophy
    Eagle, Michelle
    Straub, Volker
    Bushby, Kate
    NEUROMUSCULAR DISORDERS, 2006, 16 : S120 - S120
  • [48] Challenges in Duchenne muscular dystrophy
    Davies, KE
    NEUROMUSCULAR DISORDERS, 1997, 7 (08) : 482 - 486
  • [49] Osteopontin in Duchenne Muscular Dystrophy
    Pegoraro, Elena
    Bello, Luca
    Piva, Luisa
    Barp, Andrea
    Ermani, Mario
    Politano, Luisa
    Mercuri, Eugenio
    Previtali, Stefano
    Torrente, Yvan
    Bruno, Claudio
    Minetti, Carlo
    Berardinelli, Angela
    Comi, Giacomo
    D'Amico, Adele
    Soraru', Gianni
    Messina, Sonia
    Mongini, Tiziana
    Bertini, Enrico
    Ferlini, Alessandra
    Gualandi, Francesca
    Battini, Roberta
    Boffi, Patrizia
    Pane, Marika
    Vita, Giuseppe
    Hoffman, Eric
    Angelini, Corrado
    NEUROLOGY, 2012, 78
  • [50] Duchenne muscular dystrophy and epilepsy
    Costa, L. M.
    Barcelos, B. C.
    Cruz, A. R. S.
    Pereira, V. B. P.
    Godoy, A. J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S300 - S300